Big Antibody Deals Offer Hope Amid Challenging Times For China Biotech

Funding, Geopolitical, COVID Overhangs

 
• By Brian Yang

Recent antibody mega-deals are providing a rare bright spot for the embattled China biotech sector, amid sharply rising COVID-19 deaths in the country that indicate rebound and recovery could take longer than previously expected.

China airport empty during COVID Zero policy era
With China COVID deaths soaring, biotech sector relief still not in sight • Source: Shutterstock

More from China

More from Focus On Asia